**Supplement**

**Supplementary Table 1 Comparison of surrogate scores of advanced fibrosis in PLWH with and without NAFLD**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **No Steatosis** **(n = 182; 64.5%)** | **NAFLD** **(n = 76; 27%)** |  |
| **Variable** | **n (%)** | **n (%)** | **p-value** |
| **Surrogate Scores of Advanced fibrosis**  |  |  |  |
| **NFS n = 140** |  |  |  |
| > -1.455 | 25 (26.6) | 23 (50) | **0.006** |
|  |  |  | **0.019** |
|  < -1.455 | 69 (73.4) | 23 (50.0) |  |
|  - 1.455 to 0.675 | 23 (24.5) | 20 (43.5) |  |
|  > 0.675 | 2 (2.1) | 3 (6.5) |  |
|  |  |  |  |
| **FIB-4 n = 262** |  |  |  |
|  > 1.3 | 62 (36.9) | 24 (33.3) | 0.597 |
|  |  |  | 0.900 |
|  < 1.45 | 119 (96) | 53 (96.4) |  |
|  > 3.25 | 5 (4.0) | 2 (3.6) |  |

Data are expressed as numbers and percentage (%). NFS, NAFLD-Fibrosis score; FIB4, Fibrosis-4. A chi-square test was used to compare categorical values. Boldface indicates statistical significance. A p-value < 0.05 was considered statistically significant.



**Supplementary Figure 1 Prevalence of hepatic steatosis and fibrosis in PLWH in Germany.** Steatosis was present in 35.5% of PLWH (A). Significant fibrosis (LSM ≥ 8.2 kPa) was detected in 6.7% of PLWH (B). CAP, controlled attenuation parameter (dB/m); LSM, liver stiffness measurement (kPa).

****

**Supplementary Figure 2 Prevalence of steatohepatitis in PLWH in Germany.** The FAST score ruled out steatohepatitis in 231 (87.8%) PLWH (cut-off < 0.35). A total of 32 (12.1%) PLWH had a cut-off of > 0.35, of whom 9.1% (n = 24) and 3.0% (n = 8) showed a cut-off > 0.35 - < 0.67 and ≥ 0.67, respectively.